<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">Second cancer</z:e> has been associated with non-Hodgkin's <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (NHL) treatment, but few studies have addressed this issue considering specific treatments </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: We estimated risk by standardized incidence ratios (SIR) and absolute excess risk (AER) based on general population rates (European Network of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registries) in 748 patients (aged 15-82 years) treated for aggressive NHL in four successive EORTC (European Organization for Research on Treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>) trials </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> patients received fully-dosed CHOP-like chemotherapy, 65% received involved-field radiotherapy and 14% high-dose treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Half of the patients needed salvage treatment and 37% were followed for more than 10 years </plain></SENT>
<SENT sid="4" pm="."><plain>The cause of <z:hpo ids='HP_0011420'>death</z:hpo> was NHL in 79% of the patients; 4% died of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancer</z:e> (median survival 8.9 (0.8- 20.5) years) </plain></SENT>
<SENT sid="5" pm="."><plain>Cumulative incidences (<z:hpo ids='HP_0011420'>death</z:hpo> from any cause being a competing event) were 5% and 11% for solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and 1% and 3% for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> at 10 and 15 years, respectively </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> risk appeared age-related: in young patients high risks were observed for <z:hpo ids='HP_0001909'>leukemia</z:hpo> (SIR 16.7,95% CI 1.4-93.1,AER 5.0), Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (SIR 60.1,95% CI 12.4-175.2, AER 15.7), <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (SIR 12.5, 95% CI 2.6-36.5, AER 14.7) and <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> (SIR 15.4; 95% CI 4.2-39.4, AER 19.8), while risk in patients older than 45 years matched than that in the <z:mpath ids='MPATH_458'>normal</z:mpath> population </plain></SENT>
<SENT sid="7" pm="."><plain>The risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was significantly raised by smoking and salvage treatment </plain></SENT>
<SENT sid="8" pm="."><plain>INTERPRETATION AND CONCLUSIONS: Half of the patients die of aggressive NHL before living long enough to experience <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Only young patients have a high risk of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancer</z:e> during follow-up beyond 10 years </plain></SENT>
</text></document>